A novel monoclonal antibody developed by US researchers has demonstrated strong protection against malaria in an early clinical trial, raising hopes for a new preventive approach against the deadly disease.

The antibody, named MAM01, was tested by researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD). The trial found that MAM01 provided dose-dependent full protection against the malaria parasite with minimal side effects.

“This new monoclonal antibody could transform how we prevent malaria in young children and pregnant women,” said Kirsten E. Lyke, lead author and Professor of Medicine at the university. “Unlike vaccines that may require multiple doses or boosters, a single injection of a long-acting antibody could provide

See Full Page